NCT01159171View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Colorectal Cancer
Interventions
DRUG

bevacizumab [Avastin]

5 mg/kg intravenously every 14 days

DRUG

capecitabine [Xeloda]

1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle

DRUG

oxaliplatin

40 mg/m2 iv weekly

Trial Locations (6)

10126

Torino

33081

Aviano

47900

Rimini

61032

Fano

90146

Palermo

00135

Roma

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01159171 - A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. | Biotech Hunter | Biotech Hunter